Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD). No liver injury has been observed with tolvaptan treatment in healthy subjects and in non-ADPKD indications, but ADPK...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodhead, Jeffrey L., Brock, William J., Roth, Sharin E., Shoaf, Susan E., Brouwer, Kim L.R., Church, Rachel, Grammatopoulos, Tom N., Stiles, Linsey, Siler, Scott Q., Howell, Brett A., Mosedale, Merrie, Watkins, Paul B., Shoda, Lisl K.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Mechanisms of Tolvaptan-Induced Liver Injury
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216653/
https://www.ncbi.nlm.nih.gov/pubmed/27655350
http://dx.doi.org/10.1093/toxsci/kfw193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216653/
https://www.ncbi.nlm.nih.gov/pubmed/27655350
http://dx.doi.org/10.1093/toxsci/kfw193

Ejemplares similares